deferiprone

出典: meddic

デフェリプロン

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

英文文献

  • Iron distribution and histopathological characterization of the liver and heart of β-thalassemic mice with parenteral iron overload: Effects of deferoxamine and deferiprone.
  • Yatmark P1, Morales NP2, Chaisri U3, Wichaiyo S1, Hemstapat W1, Srichairatanakool S4, Svasti S5, Fucharoen S5.
  • Experimental and toxicologic pathology : official journal of the Gesellschaft für Toxikologische Pathologie.Exp Toxicol Pathol.2014 Sep;66(7):333-43. doi: 10.1016/j.etp.2014.03.002. Epub 2014 Jun 3.
  • The liver and heart are the major target organs for iron accumulation and iron toxicity in β-thalassemia. To mimic the phenomenon of heavy iron overload resulting from repeated blood transfusions, a total of 180mg of iron dextran was intraperitoneally injected into C57BL/6J mice (WT) and heterozygo
  • PMID 24907196
  • A new deferiprone controlled release system obtained by ultrasound-assisted compression.
  • Aguilar-De-Leyva A1, Gonçalves-Araujo T, Daza V, Caraballo I.
  • Pharmaceutical development and technology.Pharm Dev Technol.2014 Sep;19(6):728-34. doi: 10.3109/10837450.2013.829091. Epub 2013 Aug 28.
  • OBJECTIVES: This study implements the design of an innovative dosage form using ultrasound-assisted compression of thermoplastic polymers and the development of controlled release tablets for the oral administration of deferiprone in two doses per day.METHODS: Binary matrix tablets containing deferi
  • PMID 23984972
  • Targeting chelatable iron as a therapeutic modality in Parkinson's disease.
  • Devos D1, Moreau C, Devedjian JC, Kluza J, Petrault M, Laloux C, Jonneaux A, Ryckewaert G, Garçon G, Rouaix N, Duhamel A, Jissendi P, Dujardin K, Auger F, Ravasi L, Hopes L, Grolez G, Firdaus W, Sablonnière B, Strubi-Vuillaume I, Zahr N, Destée A, Corvol JC, Pöltl D, Leist M, Rose C, Defebvre L, Marchetti P, Cabantchik ZI, Bordet R.
  • Antioxidants & redox signaling.Antioxid Redox Signal.2014 Jul 10;21(2):195-210. doi: 10.1089/ars.2013.5593. Epub 2014 Feb 6.
  • Abstract Aims: The pathophysiological role of iron in Parkinson's disease (PD) was assessed by a chelation strategy aimed at reducing oxidative damage associated with regional iron deposition without affecting circulating metals. Translational cell and animal models provided concept proofs and a del
  • PMID 24251381

和文文献

  • Iron chelation therapy in the management of thalassemia : the Asian perspectives
  • VIPRAKASIT Vip,LEE-LEE Chan,CHONG Quah Thuan,LIN Kai-Hsin,KHUHAPINANT Archrob
  • International journal of hematology 90(4), 435-445, 2009-11-15
  • NAID 10026109273
  • Hepatitis B virus reactivation during combined therapy with deferiprone and desferioxamine in a hepatitis B surface antigen thalassemic carrier
  • RICCHI Paolo,CINQUE Patrizia,GALEOTA Alfonso Lanza,DI MATOLA Tiziana,AMMIRABILE Massimiliano,PROSSOMARITI Luciano
  • International journal of hematology 89(2), 135-138, 2009-03-15
  • NAID 10025159985

関連リンク

Ferriprox® (deferiprone) is an iron chelator indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. ... This website contains information for a ...
Deferiprone comes as a tablet to take by mouth. It is usually taken three times a day, in the morning, at mid-day, and in the evening. Deferiprone may be taken with or without food, but taking it with meals may help to prevent nausea ...

関連画像


押しても画像が表示されない場合はサーバが混雑しています。2週間ほどあけて、再度押下してください。


★リンクテーブル★
リンク元デフェリプロン

デフェリプロン」

  [★]

deferiprone
  • 細胞膜透過性の鉄キレート剤




★コメント★

[メモ入力エリア]
※コメント5000文字まで
ニックネーム:
コメント:




表示
個人用ツール


  meddic.jp

リンク
連絡